Pharmaceutical Products: approximately 65% of total revenue
Health Products: approximately 20% of total revenue
Medical Devices: approximately 15% of total revenue

TOP 3 Markets:

1. China: approximately 70%
2. Southeast Asia: approximately 15%
3. Europe: approximately 10%

China Resources Pharmaceutical Group Limited generates the majority of its revenue from the sale of pharmaceutical products, followed by health products and medical devices. The Chinese market is the dominant market for the company, attributed to its strong local presence and the demand for pharmaceutical products in China.

Southeast Asia and Europe are also significant markets, with the company benefiting from the growing healthcare and increasing demand for medical products in these regions.

Production Sites: Mainly in China

China Resources Pharmaceutical Group Limited produces the majority of its products in China. The company has several production facilities throughout the country specializing in the manufacturing of pharmaceutical products, traditional Chinese medicines, and other health products.

This strategic placement of production sites allows the company to optimize logistics and distribution costs while ensuring proximity to key sources of raw materials and markets.

Focus on Research and Development: Increase in R&D spending by 20% (2024)

Market Expansion: Planned expansion into new markets in Southeast Asia (2025)

Digitalization: Investment in digital health platforms

China Resources Pharmaceutical Group Limited is pursuing a multi-pronged growth strategy. A key component is the increased investment in research and development, with the aim of developing innovative products and expanding the product pipeline. This is intended to strengthen the company's competitiveness and tap into new revenue sources.

Additionally, the company plans to expand its market presence in Southeast Asia. This expansion aims to benefit from the growing healthcare markets in this region and increase international reach.

Another strategic focus is on digitalization. Through investments in digital health platforms, China Resources Pharmaceutical Group Limited aims to improve the efficiency of its services and develop new digital business models to meet changing consumer needs.

Main Imported Raw Materials: Active Pharmaceutical Ingredients (APIs), Excipients, Packaging Materials

Main Import Countries: India, Germany, USA

China Resources Pharmaceutical Group Limited imports a variety of raw materials necessary for the production of their pharmaceutical products. The most important imported materials include active pharmaceutical ingredients (APIs), which are essential for the production of medications. These are mainly sourced from India, a significant supplier of APIs in the global market.

In addition, the company imports excipients and packaging materials needed for the completion and distribution of the products. These materials are often imported from Germany and the USA, known for their high-quality pharmaceutical excipients and packaging solutions.

By diversifying their supply chains, China Resources Pharmaceutical ensures access to high-quality raw materials to maintain their production standards.

Market share in China: Approximately 5% (estimated, 2025)
R&D expenses: 4% of revenue (2025)
Industry growth in China: 8% (2025)

China Resources Pharmaceutical Group Limited (CR Pharma) has a significant competitive advantage due to its strong market presence and the support of its parent company China Resources. The company benefits from a broad distribution network and a diversified product range, allowing it to cover various segments of the pharmaceutical market.

Another advantage is the continuous investment in research and development, which accounts for about 4% of revenue. This enables CR Pharma to develop innovative products and differentiate itself in a competitive market.

Despite an estimated market share of 5% in China, which is moderate compared to international standards, the company benefits from robust industry growth of 8% in China. This provides CR Pharma with the opportunity to further expand its market share and strengthen its position.

Institutional Investor Share: 55% (estimated for 2025 based on historical trends)

Insider Trades: No significant transactions in the last 12 months (as of 2025)

The institutional investor share in China Resources Pharmaceutical Group Limited is approximately 55%. This indicates a strong interest from institutional investors, reflecting confidence in the company's long-term stability and growth potential.

Regarding insider transactions, there have been no significant purchases or sales in the past year. This could suggest that the company's executives and insiders are content with the current valuation and future prospects.

Market share of China Resources Pharmaceutical Group Limited: 6.5% (2025, estimated)

Top competitors and their market shares:

1. Sinopharm Group Co. Ltd.: 12.0%
2. Shanghai Pharmaceuticals Holding Co. Ltd.: 8.5%
3. China Resources Pharmaceutical Group Limited: 6.5%
4. CSPC Pharmaceutical Group Limited: 5.2%
5. Hengrui Medicine: 4.8%
6. Fosun Pharma: 4.3%
7. Yunnan Baiyao Group Co. Ltd.: 3.9%
8. Tong Ren Tang Technologies Co. Ltd.: 3.5%
9. Harbin Pharmaceutical Group Co. Ltd.: 3.0%
10. Tasly Pharmaceutical Group Co. Ltd.: 2.7%

Moat Analysis:

China Resources Pharmaceutical Group Limited has a moderate moat, mainly driven by its strong distribution infrastructure and the support from its parent company China Resources. These factors provide a certain level of stability and market access, especially in rural and less developed areas of China.

In comparison, Sinopharm Group Co. Ltd. has a significantly stronger moat as the largest pharmaceutical wholesaler in China with a more comprehensive supply chain and a broader product portfolio. Shanghai Pharmaceuticals also benefits from a strong market presence and a diversified product line.

CSPC Pharmaceutical Group and Hengrui Medicine stand out for their innovation and strong R&D activities, giving them a competitive advantage in specific segments.

Overall, China Resources Pharmaceutical Group Limited has a solid but not outstanding moat compared to its main competitors. The competitive advantage could be further enhanced through increased investments in research and development as well as strategic partnerships.

Revenue Growth: 8.5% (2024) Profit Growth: 6.2% (2024) R&D Expenses: 5.1% of revenue (2024)

China Resources Pharmaceutical Group Limited recorded solid revenue growth of 8.5% in 2024, attributed to strong demand for pharmaceutical products and an effective distribution strategy. The 6.2% profit growth indicates the company's ability to efficiently manage costs while increasing profitability.

Furthermore, the company invests 5.1% of its revenue in research and development, signaling a strong focus on innovation and future growth. These investments could lead to new products and market share gains in the long term.

Overall, China Resources Pharmaceutical Group Limited demonstrates stable financial performance and a forward-looking strategy, making the stock a potentially good investment, especially for investors interested in long-term growth.

Dividend Yield: 3.5% (estimated for 2025)
Dividend History: Consistent payout over the last 5 years

China Resources Pharmaceutical Group Limited has regularly distributed dividends in recent years, indicating a certain level of reliability. The dividend yield is estimated to be around 3.5% for 2025, based on the payouts of recent years and current market conditions.

The company has a solid financial foundation and a strong market position, supporting the continuity of dividend payments. However, investors should also consider the overall economic situation and specific industry trends in China that could influence future dividend policy.